Replimune Group (REPL) Competitors $5.73 -0.28 (-4.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.72 -0.01 (-0.09%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock REPL vs. ADPT, TVTX, IMCR, MESO, SRPT, APGE, VCEL, BHVN, EWTX, and AUPHShould you be buying Replimune Group stock or one of its competitors? The main competitors of Replimune Group include Adaptive Biotechnologies (ADPT), Travere Therapeutics (TVTX), Immunocore (IMCR), Mesoblast (MESO), Sarepta Therapeutics (SRPT), Apogee Therapeutics (APGE), Vericel (VCEL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Replimune Group vs. Its Competitors Adaptive Biotechnologies Travere Therapeutics Immunocore Mesoblast Sarepta Therapeutics Apogee Therapeutics Vericel Biohaven Edgewise Therapeutics Aurinia Pharmaceuticals Replimune Group (NASDAQ:REPL) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Do insiders and institutionals have more ownership in REPL or ADPT? 92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by company insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, REPL or ADPT? Replimune Group has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Do analysts prefer REPL or ADPT? Replimune Group presently has a consensus price target of $6.50, indicating a potential upside of 13.44%. Adaptive Biotechnologies has a consensus price target of $12.38, indicating a potential downside of 1.86%. Given Replimune Group's higher probable upside, analysts clearly believe Replimune Group is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88 Does the media refer more to REPL or ADPT? In the previous week, Replimune Group had 26 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 35 mentions for Replimune Group and 9 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.27 beat Replimune Group's score of 0.27 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 4 Very Positive mention(s) 2 Positive mention(s) 26 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Adaptive Biotechnologies 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is REPL or ADPT more profitable? Replimune Group has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -59.07%. Adaptive Biotechnologies' return on equity of -60.93% beat Replimune Group's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% Adaptive Biotechnologies -59.07%-60.93%-23.03% Which has stronger earnings & valuation, REPL or ADPT? Adaptive Biotechnologies has higher revenue and earnings than Replimune Group. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.77Adaptive Biotechnologies$205.22M9.36-$159.49M-$0.82-15.38 SummaryAdaptive Biotechnologies beats Replimune Group on 11 of the 15 factors compared between the two stocks. Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REPL vs. The Competition Export to ExcelMetricReplimune GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$469.12M$3.20B$5.86B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-1.7721.1774.8625.97Price / SalesN/A438.17517.12182.33Price / CashN/A46.6837.5660.44Price / Book1.069.6112.156.29Net Income-$247.30M-$53.29M$3.29B$270.96M7 Day Performance-9.48%0.13%0.73%3.87%1 Month Performance12.46%5.61%4.82%4.87%1 Year Performance-48.52%10.49%60.58%26.12% Replimune Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REPLReplimune Group3.9174 of 5 stars$5.73-4.7%$6.50+13.4%-44.8%$469.12MN/A-1.77210Trending NewsADPTAdaptive Biotechnologies3.6659 of 5 stars$12.54-2.4%$12.38-1.3%+193.3%$1.96B$178.96M0.00790Positive NewsTVTXTravere Therapeutics2.995 of 5 stars$21.20-2.0%$33.43+57.7%+86.3%$1.93B$233.18M0.00460News CoveragePositive NewsAnalyst ForecastIMCRImmunocore1.8677 of 5 stars$36.64-1.5%$56.89+55.3%+6.7%$1.87B$310.20M0.00320MESOMesoblast2.0617 of 5 stars$14.55+1.1%$18.00+23.7%+132.7%$1.84B$17.20M0.0080Positive NewsGap DownSRPTSarepta Therapeutics4.4425 of 5 stars$17.60-5.9%$43.50+147.2%-86.1%$1.83B$1.90B0.001,372Trending NewsAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.9307 of 5 stars$38.42+1.5%$97.29+153.2%-25.0%$1.75BN/A0.0091News CoveragePositive NewsVCELVericel3.0516 of 5 stars$33.22-2.4%$60.40+81.8%-27.3%$1.72B$237.22M283.75300BHVNBiohaven3.2784 of 5 stars$14.50-8.7%$55.71+284.4%-61.0%$1.68BN/A-1.89239Trending NewsGap DownHigh Trading VolumeEWTXEdgewise Therapeutics2.8098 of 5 stars$14.88-4.4%$40.55+172.5%-19.0%$1.64BN/A0.0060Positive NewsAUPHAurinia Pharmaceuticals2.9246 of 5 stars$12.30-0.8%$12.00-2.4%+93.6%$1.63B$235.13M24.31300News CoveragePositive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Travere Therapeutics Alternatives Immunocore Alternatives Mesoblast Alternatives Sarepta Therapeutics Alternatives Apogee Therapeutics Alternatives Vericel Alternatives Biohaven Alternatives Edgewise Therapeutics Alternatives Aurinia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REPL) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
